FDA CGM Recall 2025-2026: Libre 3 Sensors, Dexcom Warning, 7 Deaths

Technology · 4 · March 21, 2026

A Timeline of the CGM Safety Crisis

2025-2026 has been the most turbulent period in CGM history. Both of the world's two largest CGM manufacturers — Abbott (FreeStyle Libre) and Dexcom — received FDA enforcement actions. Here's exactly what happened:

March 2025: Dexcom's Unauthorized Coating Change

The FDA issued a warning letter to Dexcom after discovering that the company had made an unauthorized change to the glucose-limiting membrane coating on their CGM sensors — without notifying the FDA or conducting required testing. The changed sensors failed on all accuracy performance metrics during post-market testing.

In plain English: Dexcom changed a critical component of how their sensors measure glucose, didn't tell the FDA, and the new sensors were less accurate than the originals. Two class-action lawsuits (Wisnerbaum and Nigh Goldenberg) are now pending on behalf of patients who relied on inaccurate readings for insulin dosing decisions.

Newsweek investigated and found multiple cases of patients experiencing dangerous discrepancies — including one where a Dexcom G7 showed 140 mg/dL when actual blood glucose was 34 mg/dL. The patient collapsed.

November 2025: Abbott's Massive Recall

Abbott Diabetes Care initiated a Class I recall (the most serious type) of approximately 3 million FreeStyle Libre 3 and Libre 3 Plus sensors. The defect: sensors could provide falsely low glucose readings, potentially leading patients to:

• Eat unnecessary carbohydrates (thinking they were hypoglycemic when they weren't)
• Skip insulin doses (thinking their glucose was already low)
• Miss actual hyperglycemia (high blood sugar going undetected)

The FDA linked the defective sensors to 7 deaths and 860 injuries. The affected lot numbers span sensors distributed between May and October 2025.

February 2026: Abbott's Warning Letter

The FDA followed up with a warning letter to Abbott's manufacturing facility, citing a stunning quality control failure: Abbott was not testing finished sensors before shipping them to patients. The FDA found that Abbott's quality system did not include adequate verification that completed devices met specifications before release.

For a medical device that millions of diabetics rely on for life-or-death insulin decisions, this is a fundamental breach of manufacturing standards.

Are You Affected? How to Check

FreeStyle Libre 3 users: Check the lot number on your sensor packaging against Abbott's recall list on the FDA recall database. Affected lots were distributed May-October 2025. If you have affected sensors, stop using them immediately and contact Abbott for free replacements.

Dexcom G7 users: There is no formal recall, but the FDA warning letter means sensors manufactured during the coating change period may have reduced accuracy. If you're experiencing frequent readings that don't match fingerprick tests (differences >30 mg/dL consistently), contact Dexcom for sensor replacements.

What This Means for Indian Users

India's medical device regulator (CDSCO) does not have the same post-market surveillance infrastructure as the US FDA. This means:

• Recalled sensors that were shipped to India before the recall may still be in distribution
• Indian pharmacies (Apollo, Medplus, 1mg) may still have affected lots on shelves
• There is no equivalent Indian recall mechanism — patients must check FDA notices themselves

At ₹5,000+ per sensor, Indian patients deserve the same safety assurances as American patients. Always verify your CGM readings with a fingerprick, especially if you're using sensors purchased before November 2025. Compare safer alternatives on our CGM & Device Shop.

5 Things to Do Right Now

1. Check your lot numbers. Compare against the FDA recall list for Libre 3/3 Plus.
2. Always verify with fingerprick. Before any insulin dosing decision, confirm with a blood glucose meter.
3. Report problems. File adverse events with the FDA's MedWatch system (US) or your local regulator.
4. Consider dual monitoring. Use CGM for trends and fingerprick for absolute accuracy. Track both in our Blood Sugar Tracker.
5. Stay informed. Follow our Diabetes News & Research page for ongoing CGM safety updates.

The Bigger Picture

CGMs remain one of the most transformative tools in diabetes management. But the 2025-2026 safety crisis is a reminder that these are complex medical devices, not consumer gadgets. Treat your CGM as a powerful assistant — not an infallible authority. The fingerprick meter remains the gold standard for accuracy, and no amount of convenience should replace clinical safety.

Stay safe, stay informed, and explore our Diabetes Hub for tools that help you manage your health with both CGM data and verified fingerprick readings.